Regentis Biomaterials discloses new U.S. patent for GelrinC

Regentis Biomaterials Ltd. filed a Form 6-K as a foreign private issuer with the U.S. Securities and Exchange Commission.

Rhea-AI Filing Summary

Regentis Biomaterials Ltd. filed a Form 6-K as a foreign private issuer with the U.S. Securities and Exchange Commission. The report furnishes a press release dated December 18, 2025, titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.”

The core update is the disclosure of this new U.S. patent related to GelrinC, which is described as an off-the-shelf regenerative cartilage repair product.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Regentis Biomaterials (RGNT) report in this Form 6-K?

Regentis Biomaterials reports that it is furnishing a press release titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC” as part of this Form 6-K.

What new development does Regentis Biomaterials (RGNT) disclose about GelrinC?

The company discloses that it has been granted a new U.S. patent related to its off-the-shelf regenerative cartilage repair product GelrinC.

When was the related press release about the new U.S. patent issued?

The related press release was issued on December 18, 2025.

What type of product is GelrinC according to Regentis Biomaterials (RGNT)?

GelrinC is described as an off-the-shelf regenerative cartilage repair product.

Where is Regentis Biomaterials Ltd. located?

Regentis Biomaterials Ltd. lists its principal executive offices at 60 Medinat Hayehudim Street, 4676652, Israel.

What exhibit is included with this Regentis Biomaterials (RGNT) Form 6-K?

The Form 6-K includes Exhibit 99.1, which is the press release titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 08:48 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2025

Commission file number: 001-42834

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the registrant’s press release issued on December 18, 2025, titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.”

A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. 

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: December 18, 2025	By:	/s/ Ehud Geller
	Name:	Ehud Geller
	Title:	Chairman

3